Showing 671-680 of 2150 results for "".
- Rizatriptan Not Effective for Acute Vestibular Migraine Reliefhttps://practicalneurology.com/news/rizatriptan-not-effective-for-acute-vestibular-migraine-relief/2475105/Results from a randomized clinical trial published in JAMA Neurology found that treatment with rizatriptan was ineffective for managing acute symptoms of vestibular migraine but was modestly effective at controlling headache-related symptoms at 24 hours. This double-blind study e
- New Scholarship for Medical Students Interested in Neurology Establishedhttps://practicalneurology.com/news/new-scholarship-for-medical-students-interested-in-neurology-established/2470434/Ameer E. Hassan, DO, a professor of neurology at the University of Texas and a practicing neurologist at the Valley Baptist Medical Center-Harlingen, has established a new educational funding opportunity: the Dr. Ameer Hassan Scholarship for Medical Students. The scholarship consists of a one-tim
- Potassium Channel Modulator Reduces Focal Onset Seizure Frequency in Clinical Trialshttps://practicalneurology.com/news/potassium-channel-modulator-reduces-focal-onset-seizure-frequency-in-clinical-trials/2469954/In the phase 2b X-TOLE trial, participants ( treated with the positive allosteric modulator of the KCNQ2/3 (Kv7.2/7.3) potassium channel (XEN1101; Xenon Pharmaceuticals, Burnaby, British Columbia) had significant reduction in the frequency of focal onset seizures. Seizure reductions occurred as e
- Rapid and Sustained Seizure Termination With Midazolam in Open-Label Extension Studyhttps://practicalneurology.com/news/rapid-and-sustained-seizure-termination-with-midazolam-in-open-label-extension-study/2469769/Post hoc analysis of an open-label extension study (NCT01529034) showed treatment with midazolam nasal spray (Nayzilam; UCB Pharma, Smyrna, GA) terminated 92% of seizure cluster episodes. There was no seizure recurrence from 10 minutes of treatment to 24 hours for 85% of treated seizure cluster e
- Phase 2b Study Ending for Sublingual Ketamine for Acute Painhttps://practicalneurology.com/news/phase-2b-study-ending-for-sublingual-ketamine-for-acute-pain/2468909/The Food and Drug Administration (FDA) has scheduled an end-of-phase 2 clinical trial meeting for a sublingual formulation of racemic ketamine (Wafermine; iX Biopharma, Singapore) for treatment of moderate-to-severe acute pain. The therapy contains R and S isomers of ketamine in e
- Vamorolone Has Efficacy for Treating Duchenne Muscular Dystrophy Without Affecting Growthhttps://practicalneurology.com/news/vamorolone-has-efficacy-for-treating-duchenne-muscular-dystrophy-without-affecting-growth/2470013/In the VISION-DMD trial (NCT02760277), children with Duchenne muscular dystrophy (DMD) treated with vamorolone (ReveraGen BioPharma, Rockville, MD), had improved motor function with no negative effects on linear growth or biomarkers of
- Sargramostim Improves Motor Symptoms of Parkinson Disease in Small Phase 1 Trialhttps://practicalneurology.com/news/sargramostim-improves-motor-symptoms-of-parkinson-disease-in-small-phase-1-trial/2469597/An investigator-initiated clinical trial (NCT03790670) evaluated the use of sargramostim (Leukine; Partner Therapeutics, Lexington, MA). Improvements in MDS-UPDRS Part 3 scores, which measure motor sympto
- Validation of an Algorithmic EEG-Based Diagnostic Tool for Concussionhttps://practicalneurology.com/news/validation-of-an-algorithmic-eeg-based-diagnostic-tool-for-concussion/2469505/A study validating an EEG-based algorithmic concussion assessment tool (Concussion Index; Brainscope, Bethesda, MD) has been published in JAMA Open Network for evaluating severity of concussion
- Cannabidiol Reduces Seizures in People With Tuberous Sclerosis Complex-Related Seizures in Clinical Trialshttps://practicalneurology.com/news/cannabidiol-reduces-seizures-in-people-with-tuberous-sclerosis-complex-related-seizures-in-clinical-trials/2469097/Findings from a clinical trial (NCT02544763) presented at the American Epilepsy Society Annual Meeting December 6-10, 2019 in Baltimore, MD showed that people with tuberous sclerosis complex (TSC), a genetic condition associated with t
- Positive Phase 2 Results for Evobrutinib Treatment of MS and Initiation of Phase 3 Trialshttps://practicalneurology.com/news/positive-phase-2-results-for-evobrutinib-treatment-of-ms-and-initiation-of-phase-3-trials/2469014/At the European Committee on Research and Treatment in Multiple Sclerosis (ECTRIMS) Congress in Stockholm, Sweden September 11-13, 2019, data from a phase 2 trial (NCT02975349) of evobrutinib (EMD Serono, Rockland, MD) for treatment of